The 'state' of beta-adrenoceptors.
作者信息
Molenaar Peter
机构信息
The National Heart Foundation, Chermside, Queensland 4032, Australia.
出版信息
Br J Pharmacol. 2003 Sep;140(1):1-2. doi: 10.1038/sj.bjp.0705420. Epub 2003 Aug 4.
Abstract
摘要
相似文献
1
The 'state' of beta-adrenoceptors.β-肾上腺素能受体的“状态”
Br J Pharmacol. 2003 Sep;140(1):1-2. doi: 10.1038/sj.bjp.0705420. Epub 2003 Aug 4.
2
Pharmacological properties of beta 3-adrenoceptors.β3肾上腺素能受体的药理学特性。
Trends Pharmacol Sci. 1997 Jul;18(7):257-8.
3
4
5
The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung in vitro.大鼠心脏和肺中β-1和β-2肾上腺素能受体的体外药理学特异性
Mol Pharmacol. 1979 Jul;16(1):21-33.
6
[Beta 3-receptors: incidence and properties, possible clinical significance].
Tidsskr Nor Laegeforen. 1995 Jan 10;115(1):45-9.
7
Adrenoceptors--classification, activation and blockade by drugs.肾上腺素能受体——药物的分类、激活与阻断
Postgrad Med J. 1980;56 Suppl 2:7-16.
8
Thermodynamics of agonist and antagonist interactions with mammalian beta-adrenergic receptors.激动剂和拮抗剂与哺乳动物β-肾上腺素能受体相互作用的热力学
Mol Pharmacol. 1980 Nov;18(3):341-7.
9
[Adrenergic receptor--classification, agonists and antagonists].[肾上腺素能受体——分类、激动剂与拮抗剂]
Kokyu To Junkan. 1992 Jan;40(1):3-9.
10
Pharmacological criteria for the detection of beta 3-adrenoceptors.检测β3肾上腺素能受体的药理学标准。
Trends Pharmacol Sci. 1997 Feb;18(2):52-3. doi: 10.1016/s0165-6147(96)01024-3.
引用本文的文献
1
Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.肾上腺素能受体：受体、配体及其临床用途，分子药理学和检测。
Handb Exp Pharmacol. 2024;285:55-145. doi: 10.1007/164_2024_713.
2
Introduction: A Short History of Adrenoceptor Research.引言：肾上腺素能受体研究简史。
Handb Exp Pharmacol. 2024;285:1-12. doi: 10.1007/164_2024_718.
3
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.鉴定跨膜 4 中负责人类β1-肾上腺素能受体次要、低亲和力构象的关键残基。
Mol Pharmacol. 2014 May;85(5):811-29. doi: 10.1124/mol.114.091587. Epub 2014 Mar 7.
4
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.多态性变体对人β1-肾上腺素能受体两种激动剂构象分子药理学的影响。
PLoS One. 2013 Nov 8;8(11):e77582. doi: 10.1371/journal.pone.0077582. eCollection 2013.
5
Non-traditional roles of G protein-coupled receptors in basic cell biology.G蛋白偶联受体在基础细胞生物学中的非传统作用。
Mol Biosyst. 2013 Apr 5;9(4):586-95. doi: 10.1039/c2mb25429h.
6
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.从细胞检测预测β受体阻滞剂的体内心血管特性：细胞和心血管药理学反应的定量比较。
FASEB J. 2011 Dec;25(12):4486-97. doi: 10.1096/fj.11-192435. Epub 2011 Aug 24.
7
The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor. turkey β-肾上腺素能受体结晶所必需的热稳定（m23）突变和细胞内外（β36）缺失的药理学效应。
Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384(1):71-91. doi: 10.1007/s00210-011-0648-4. Epub 2011 May 6.
8
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.β 受体阻滞剂的演进：从抗心绞痛药物到配体定向信号转导。
Trends Pharmacol Sci. 2011 Apr;32(4):227-34. doi: 10.1016/j.tips.2011.02.010. Epub 2011 Mar 21.
9
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.三种火鸡β-肾上腺素能受体的全面药理学分析，并与人β-肾上腺素能受体进行比较。
PLoS One. 2010 Nov 30;5(11):e15487. doi: 10.1371/journal.pone.0015487.
10
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.β-肾上腺素受体激动剂在人β1、β2 和β3-肾上腺素受体上的选择性。
Br J Pharmacol. 2010 Jul;160(5):1048-61. doi: 10.1111/j.1476-5381.2010.00754.x.
本文引用的文献
1
Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery.非典型β-肾上腺素能受体不同于β3-肾上腺素能受体，可能也不同于β1-肾上腺素能受体的低亲和力状态，它能使大鼠离体肠系膜动脉舒张。
Br J Pharmacol. 2003 Sep;140(1):3-12. doi: 10.1038/sj.bjp.0705421. Epub 2003 Aug 4.
2
Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer.通过生物发光共振能量转移对β1-和β2-肾上腺素能受体同源和异源二聚化进行定量评估。
J Biol Chem. 2002 Nov 22;277(47):44925-31. doi: 10.1074/jbc.M205767200. Epub 2002 Sep 19.
3
Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.在双β1/β2肾上腺素能受体基因敲除小鼠中消除（-）-CGP 12177诱发的心脏刺激作用。β1肾上腺素能受体在假定的β4肾上腺素能受体药理学中的必要作用。
Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):87-93. doi: 10.1007/s002100000336.
4
5
Metabolic response to various beta-adrenoceptor agonists in beta3-adrenoceptor knockout mice: evidence for a new beta-adrenergic receptor in brown adipose tissue.β3 -肾上腺素能受体基因敲除小鼠对各种β -肾上腺素能受体激动剂的代谢反应：棕色脂肪组织中一种新的β -肾上腺素能受体的证据
Br J Pharmacol. 1998 Aug;124(8):1684-8. doi: 10.1038/sj.bjp.0702007.
6
(-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice.（-）-CGP 12177在野生型和β3肾上腺素能受体基因敲除小鼠中均引起心脏兴奋，并与心脏假定的β4肾上腺素能受体结合。
Mol Pharmacol. 1998 Apr;53(4):670-5. doi: 10.1124/mol.53.4.670.
7
Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat.大鼠心脏第三种β-肾上腺素能受体与结肠β3-肾上腺素能受体之间的差异
Br J Pharmacol. 1996 Aug;118(8):2085-98. doi: 10.1111/j.1476-5381.1996.tb15648.x.
8
Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors.与β3肾上腺素能受体不同的非典型β肾上腺素能受体介导CGP 12177和氰吲哚洛尔对去大脑大鼠的正性变时作用。
Br J Pharmacol. 1996 Mar;117(5):943-9. doi: 10.1111/j.1476-5381.1996.tb15285.x.
9
Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors.CGP 12177A对β1-肾上腺素能受体的异常作用。
J Recept Signal Transduct Res. 1996 Jan-Mar;16(1-2):1-23. doi: 10.3109/10799899609039938.
10
Is there a third heart beta-adrenoceptor?是否存在第三种心脏β-肾上腺素能受体？
Trends Pharmacol Sci. 1989 Aug;10(8):316-20. doi: 10.1016/0165-6147(89)90065-5.
Zotero 插件